Full-Year 2024 Revenue Guidance (1) Range of $58.5 to $61.5 Billion Includes Expected Contribution from Seagen Acquisition Anticipates Approximately $8 Billion in Revenues for Comirnaty (2) and Paxlovid Seagen Expected to Contribute Approximately $3.1 Bi
The company responded with a $43 billion purchase of cancer drugmaker Seagen, cost cuts, and an internal restructuring that prioritized its cancer drugs. In February, the New York-based drugmaker said its cancer unit would have at least eight blockbuster drugs by 2030, up from five currently...
In terms of achievements, there were many. Among them, approximately 618 million patients around the world were treated with Pfizer medicines and vaccines in 20231; we received a record number of FDA approvals for new molecular entities; and we completed our acquisition of Seagen, a critical ste...
“In addition, we completed the acquisition of Seagen inDecember 2023, a critical step toward our goal to achieve world-class Oncology leadership. With the combined strength of Pfizer’s and Seagen’s talent, portfolios and platforms, we believe we have the potential to transf...
No prospectus, offering circular or other document has been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, neither this press release nor any document or material in connection with the offer or sale, or invitation for subscription or purchase, of the Notes, may...
purchaseof Effexor XR or generic25PFIZER INC.AND SUBSIDIARY COMPANIESNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(UNAUDITED)Effexor XR from any of the defendants from June 14,2008 until the time the defendants allegedly unlawful 270、 conduct ceased.The plaintiffs in all of the actionsallege ...
approvals of Penbraya, Velsipity and of the Braftovi+Mektovi combination in BRAF-mutated metastatic non-small cell lung cancer; and EC approval of Litfulo. -1- "In addition, we continue to make progress toward our proposed acquisition of Seagen, a global leader in discovering, developing ...